IL6R and rheumatoid arthritis: Convincing clinical benefits have been currently obtained only for the IL-6R blocker tocilizumab in patients with RA-related or ANCA-associated nephropathy, whereas information on other drugs and indications is still insufficient for evidence-based conclusions.